AHA 22 - CardioNerds Fellow, Dr Kahtan Fadah (Texas Tech University, US) is joined by PREVENT-HD PI, Dr Gregory Piazza (Brigham and Women's Hospital, US) to discuss the findings revealed at AHA 2022.

PREVENT-HD was designed to evaluate the safety and efficacy of rivaroxaban in reducing the risk of major venous and arterial thrombotic events in patients with COVID-19. Over 1200 patients were randomized to receive either rivaroxaban, placebo or standard care for COVID-19.

The study showed that rivaroxaban, prescribed for 35 days in non-hospitalized patients with symptomatic COVID-19 at-risk for thrombosis, did not reduce a composite endpoint of venous and arterial thrombotic events, hospitalisation and death.

Access our full AHA 22 Scientific Coverage here.  

Recorded Remotely from Lubbock and Boston, 2022.

Editor: Jordan Rance and Mirjam Boros
Video Specialist: Dan Brent and Oliver Miles